[go: up one dir, main page]

IN2014DN09134A - - Google Patents

Info

Publication number
IN2014DN09134A
IN2014DN09134A IN9134DEN2014A IN2014DN09134A IN 2014DN09134 A IN2014DN09134 A IN 2014DN09134A IN 9134DEN2014 A IN9134DEN2014 A IN 9134DEN2014A IN 2014DN09134 A IN2014DN09134 A IN 2014DN09134A
Authority
IN
India
Prior art keywords
mir
compositions
activity
fibrosis
inhibition
Prior art date
Application number
Other languages
English (en)
Inventor
Balkrishen Bhat
Eric Marcusson
Original Assignee
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN09134(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regulus Therapeutics Inc filed Critical Regulus Therapeutics Inc
Publication of IN2014DN09134A publication Critical patent/IN2014DN09134A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
IN9134DEN2014 2012-04-25 2013-04-24 IN2014DN09134A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261741783P 2012-04-25 2012-04-25
US201261717927P 2012-10-24 2012-10-24
US201361779913P 2013-03-13 2013-03-13
PCT/US2013/037913 WO2013163258A1 (fr) 2012-04-25 2013-04-24 Composés microarn et méthodes pour la modulation de l'activité du mir-21

Publications (1)

Publication Number Publication Date
IN2014DN09134A true IN2014DN09134A (fr) 2015-05-22

Family

ID=48289681

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9134DEN2014 IN2014DN09134A (fr) 2012-04-25 2013-04-24

Country Status (28)

Country Link
US (5) US8969317B2 (fr)
EP (1) EP2841579B1 (fr)
JP (1) JP6322189B2 (fr)
KR (4) KR20230037703A (fr)
CN (1) CN104254607B (fr)
AR (1) AR090825A1 (fr)
AU (1) AU2013251696B2 (fr)
BR (1) BR112014026639A8 (fr)
CA (1) CA2869639A1 (fr)
CL (3) CL2014002844A1 (fr)
CO (1) CO7111303A2 (fr)
CR (1) CR20140524A (fr)
DO (1) DOP2014000233A (fr)
EA (1) EA030211B1 (fr)
EC (1) ECSP14028612A (fr)
GT (1) GT201400221A (fr)
IL (1) IL234904B (fr)
IN (1) IN2014DN09134A (fr)
MX (1) MX353562B (fr)
MY (1) MY173600A (fr)
NZ (1) NZ630591A (fr)
PE (1) PE20142404A1 (fr)
PH (2) PH12023550488A1 (fr)
SG (1) SG11201406931XA (fr)
TW (1) TWI647235B (fr)
UA (1) UA117098C2 (fr)
WO (1) WO2013163258A1 (fr)
ZA (1) ZA201407228B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3321361B1 (fr) 2010-02-08 2019-03-27 Ionis Pharmaceuticals, Inc. Réduction sélective de variants alléliques
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (fr) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Synthese d'acides nucleiques et methodes d'utilisation associees
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
DK2702155T3 (en) 2011-04-25 2017-05-01 Regulus Therapeutics Inc MICRO-RNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
SI2791160T1 (sl) 2011-12-16 2022-07-29 Modernatx, Inc. Sestave modificirane MRNA
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9193971B2 (en) * 2012-04-10 2015-11-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for the treatment of nonalcoholic steatohepatitis
NZ630591A (en) 2012-04-25 2017-02-24 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
US20150275208A1 (en) * 2012-10-12 2015-10-01 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
US9994846B2 (en) 2013-10-25 2018-06-12 Regulus Therapeutics Inc. MicroRNA compounds and methods for modulating miR-21 activity
TW201610152A (zh) * 2013-11-22 2016-03-16 國立臺灣大學 微ｒｎａ１４６－ａ及其於診斷、治療及預防小核醣核酸病毒感染之用途及微ｒｎａ１４６－ａ拮抗劑
EP3105327A4 (fr) * 2014-02-12 2017-10-18 Thomas Jefferson University Compositions et procédés d'utilisation d'inhibiteurs de micro-arn
WO2015154002A1 (fr) * 2014-04-04 2015-10-08 Ohio State Innovation Foundation Compositions de nanoparticules lipidiques oligonucléotidiques, méthodes de fabrication et méthodes d'utilisation associées
CN105087477A (zh) * 2015-05-21 2015-11-25 王松灵 miR-21反义核苷酸修饰的骨髓间充质干细胞的用途
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
CN116585344A (zh) * 2017-05-04 2023-08-15 赛诺菲 用于治疗奥尔波特综合征的方法
EP3841220A1 (fr) 2018-08-23 2021-06-30 Roche Innovation Center Copenhagen A/S Biomarqueur de microarn-134
TW202031268A (zh) * 2018-11-13 2020-09-01 美商雷格勒斯治療公司 用於調節mir-10b 活性之微小rna 化合物及方法
JP7692829B2 (ja) 2019-07-30 2025-06-16 塩野義製薬株式会社 Ｍｕｒｆ１を標的とする核酸医薬
KR102293777B1 (ko) * 2019-12-31 2021-08-25 연세대학교 산학협력단 신규한 UQCRB-관련 순환 miRNA 바이오 마커 및 이를 이용한 대장암의 진단 방법
CA3168954A1 (fr) * 2020-04-09 2021-10-14 Stefan Engelhardt Administration ciblee d'un inhibiteur de mir-21 a des macrophages pour le traitement de la fibrose pulmonaire
US11965162B2 (en) 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
KR102328770B1 (ko) * 2020-06-01 2021-11-19 고려대학교 산학협력단 비알코올 지방간염 진단용 바이오마커 miRNA-4449
WO2021262919A2 (fr) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York Microarn modifiés par 5-halogéno-uracile et leur utilisation dans le traitement du cancer
KR20220014004A (ko) * 2020-07-28 2022-02-04 고려대학교 산학협력단 microRNA조합을 이용한 비알코올 지방간염 진단용 바이오마커
WO2022072336A1 (fr) * 2020-10-01 2022-04-07 University Of Washington Molécules de type médicament et méthodes pour le ciblage thérapeutique de micro-arn-21
WO2025110217A1 (fr) * 2023-11-22 2025-05-30 国立大学法人東海国立大学機構 Agent prophylactique et/ou thérapeutique pour maladies kystiques rénales

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ296262B6 (cs) 1998-05-22 2006-02-15 Boys Town National Research Hospital Farmaceutický prostredek
US20060008817A1 (en) 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
IL161100A0 (en) 2001-09-28 2004-08-31 Max Planck Gesellschaft Identification of novel genes coding for small temporal rnas
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
EP1648914A4 (fr) 2003-07-31 2009-12-16 Regulus Therapeutics Inc Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants
ATE555118T1 (de) 2003-08-28 2012-05-15 Takeshi Imanishi Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
AU2005250432B2 (en) 2004-05-28 2011-09-15 Asuragen, Inc. Methods and compositions involving microRNA
WO2006020768A2 (fr) 2004-08-10 2006-02-23 Alnylam Pharmaceuticals, Inc. Oligonucleotides chimiquement modifies
JP2008512463A (ja) 2004-09-08 2008-04-24 ボーイズ タウン ナショナル リサーチ ホスピタル マトリックスメタロプロテイナーゼ−１２に関連する糸球体基底膜疾患の治療
CA2857881A1 (fr) 2004-11-12 2006-12-28 Asuragen, Inc. Procedes et compositions comprenant des molecules de micro-arn et des molecules d'inhibiteur de micro-arn
EP1959012A3 (fr) 2004-12-29 2009-12-30 Exiqon A/S Nouvelles compositions oligonucléotides et séquences de sonde utiles pour la détection et l'analyse de micro ARN et leurs ARN cibles
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
DK1931780T3 (en) * 2005-08-29 2016-01-25 Regulus Therapeutics Inc Antisense-forbindelser med forøget anti-microrna-aktivitet
EP1984381B1 (fr) 2006-01-27 2010-09-29 Isis Pharmaceuticals, Inc. Analogues d'acides nucleiques bicycliques modifies en position 6
JP5213723B2 (ja) 2006-01-27 2013-06-19 アイシス ファーマシューティカルズ， インコーポレーテッド マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物
ES2569558T3 (es) 2006-04-03 2016-05-11 Roche Innovation Center Copenhagen A/S Composición farmacéutica que comprende oligonucleótidos antisentido anti-ARNmi
MX2008012219A (es) * 2006-04-03 2008-10-02 Santaris Pharma As Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
WO2008042973A2 (fr) 2006-10-03 2008-04-10 Alnylam Pharmaceuticals, Inc. Formulations contenant un lipide
US8906870B2 (en) 2006-10-09 2014-12-09 Julius-Maximilians-Universitaet Wuerzberg MicroRNA (miRNA) for the diagnosis and treatment of heart diseases
WO2008073920A2 (fr) 2006-12-08 2008-06-19 Asuragen, Inc. Gènes et voies génétiques régulés par mir-21 utilisés en tant que cibles pour une intervention thérapeutique
EP2118118B1 (fr) 2007-01-19 2017-09-27 Exiqon A/S Apport cellulaire médié d'oligonucléotides de lna
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
WO2008151631A2 (fr) 2007-06-15 2008-12-18 Exiqon A/S Utilisation de courts oligonucléotides pour des expériences à redondance de réactif dans une analyse fonctionnelle d'arn
US8278283B2 (en) 2007-07-05 2012-10-02 Isis Pharmaceuticals, Inc. 6-disubstituted or unsaturated bicyclic nucleic acid analogs
AU2008306327B2 (en) * 2007-10-04 2014-05-15 Roche Innovation Center Copenhagen A/S Micromirs
JP5535076B2 (ja) * 2007-10-29 2014-07-02 レグルス・セラピューティクス・インコーポレイテッド 肝臓癌を治療するための標的化ミクロｒｎａ
WO2009091972A2 (fr) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Oligonucléotides modifiés chimiquement et petites molécules à utiliser dans la réduction des taux d'activité de microarn et leurs utilisations
JP2011510678A (ja) 2008-02-08 2011-04-07 プロセンサ ホールディング ビーブイ Ｄｎａ反復不安定性関連遺伝性障害を治療するための方法及び手段
EP2096171A1 (fr) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg Cibles microARN (miARN) et en aval à des fins de diagnostic et thérapeutiques
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
CA2753562A1 (fr) 2009-02-26 2010-09-02 The Ohio State University Research Foundation Microarn chez les non-fumeurs et methodes et matieres apparentees
US20120148664A1 (en) 2009-06-08 2012-06-14 Miragen Therapeutics Chemical modifications motifs for mirna inhibitors and mimetics
WO2011126842A2 (fr) 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Ciblage de micro-arn pour le traitement de troubles cardiaques
DK2702155T3 (en) * 2011-04-25 2017-05-01 Regulus Therapeutics Inc MICRO-RNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY
WO2013013165A2 (fr) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Utilisation de composés d'acide nucléique bloqué (lna) pour l'inhibition thérapeutique de mir-21 dans le lupus érythémateux systémique
NZ630591A (en) 2012-04-25 2017-02-24 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
CA2886116C (fr) 2012-09-26 2022-06-07 Mirrx Therapeutics Oligomeres a profil hors cible ameliore
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта

Also Published As

Publication number Publication date
EP2841579A1 (fr) 2015-03-04
PE20142404A1 (es) 2015-02-02
MX353562B (es) 2018-01-17
US9267137B2 (en) 2016-02-23
PH12014502387A1 (en) 2014-12-22
KR20150003846A (ko) 2015-01-09
MY173600A (en) 2020-02-08
CL2017001195A1 (es) 2018-01-26
CN104254607B (zh) 2020-10-27
EP2841579B1 (fr) 2018-10-10
KR102118429B1 (ko) 2020-06-03
GT201400221A (es) 2018-01-17
IL234904B (en) 2019-10-31
CA2869639A1 (fr) 2013-10-31
TW201345918A (zh) 2013-11-16
NZ630591A (en) 2017-02-24
AU2013251696B2 (en) 2018-11-15
EA201491953A1 (ru) 2015-06-30
UA117098C2 (uk) 2018-06-25
PH12023550488A1 (en) 2024-06-24
IL234904A0 (en) 2014-12-31
SG11201406931XA (en) 2014-11-27
WO2013163258A1 (fr) 2013-10-31
US9688985B2 (en) 2017-06-27
CL2019001878A1 (es) 2019-12-06
DOP2014000233A (es) 2014-12-31
ECSP14028612A (es) 2015-09-30
HK1207115A1 (en) 2016-01-22
EA030211B1 (ru) 2018-07-31
CN104254607A (zh) 2014-12-31
BR112014026639A2 (pt) 2017-06-27
MX2014012476A (es) 2014-12-08
US20180305691A1 (en) 2018-10-25
AR090825A1 (es) 2014-12-10
US9970009B2 (en) 2018-05-15
ZA201407228B (en) 2017-05-31
US20170240891A1 (en) 2017-08-24
KR102369722B1 (ko) 2022-03-04
KR20220028183A (ko) 2022-03-08
US8969317B2 (en) 2015-03-03
US20150218558A1 (en) 2015-08-06
CL2014002844A1 (es) 2015-02-13
AU2013251696A1 (en) 2014-10-16
US20130289093A1 (en) 2013-10-31
CR20140524A (es) 2015-02-12
CO7111303A2 (es) 2014-11-10
JP6322189B2 (ja) 2018-05-09
US20160244753A1 (en) 2016-08-25
TWI647235B (zh) 2019-01-11
KR20200064164A (ko) 2020-06-05
JP2015519891A (ja) 2015-07-16
BR112014026639A8 (pt) 2018-01-16
KR20230037703A (ko) 2023-03-16

Similar Documents

Publication Publication Date Title
IN2014DN09134A (fr)
MX2022000212A (es) Compuestos de microarn y metodos para modular la actividad de mir-21.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
CA2871471C (fr) Inhibiteurs d'adn pk
PH12015500963A1 (en) Tricyclic fused thiophene derivatives as jak inhibitors
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
MX353299B (es) Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.
MX2014013752A (es) Inhibidores de nampt.
PH12014502513A1 (en) Nampt inhibitors
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
EP4470617A3 (fr) Pharmacophore pour induction de trail
IN2015DN01151A (fr)
MX348311B (es) Inhibidores nampt.
MX2014013758A (es) Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
IN2014DN08443A (fr)
TN2014000401A1 (en) Microrna compounds and methods for modulating mir-21 activity
MY192305A (en) Bipyrazole derivatives as jak inhibitors